CLEARSIDE BIOMEDICAL INC (CLSD) Stock Price, Forecast & Analysis
USA - NASDAQ:CLSD - US1850632035 - Common Stock
CLSD Key Statistics, Chart & Performance
The current stock price of CLSD is 2.61 USD. In the past month the price decreased by -31.32%. In the past year, price decreased by -83.89%.
CLSD Latest News, Press Relases and Analysis
CLSD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.44 | 987.43B | ||
| JNJ | JOHNSON & JOHNSON | 19.56 | 489.06B | ||
| MRK | MERCK & CO. INC. | 10.78 | 237.21B | ||
| PFE | PFIZER INC | 7.62 | 138.73B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7 | 93.51B | ||
| ZTS | ZOETIS INC | 18.28 | 51.36B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.34 | 22.39B | ||
| VTRS | VIATRIS INC | 4.37 | 11.88B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.13 | 10.55B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.28 | 7.91B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.15B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 3.81B |
Related stock screener links
About CLSD
Company Profile
Clearside Biomedical, Inc. is a biopharmaceutical company that delivers therapies to the back of the eye through the suprachoroidal space. The company is headquartered in Alpharetta, Georgia and currently employs 32 full-time employees. The company went IPO on 2016-06-02. The firm's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The firm is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The firm's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD). The company developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
Company Info
CLEARSIDE BIOMEDICAL INC
900 North Point Parkway, Suite 200
Alpharetta GEORGIA 30005 US
CEO: George Lasezkay
Employees: 32
Phone: 16782703631
CLEARSIDE BIOMEDICAL INC / CLSD FAQ
What does CLSD do?
Clearside Biomedical, Inc. is a biopharmaceutical company that delivers therapies to the back of the eye through the suprachoroidal space. The company is headquartered in Alpharetta, Georgia and currently employs 32 full-time employees. The company went IPO on 2016-06-02. The firm's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The firm is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The firm's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD). The company developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
What is the current price of CLSD stock?
The current stock price of CLSD is 2.61 USD. The price decreased by -8.74% in the last trading session.
Does CLEARSIDE BIOMEDICAL INC pay dividends?
CLSD does not pay a dividend.
What is the ChartMill rating of CLEARSIDE BIOMEDICAL INC stock?
CLSD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists CLSD stock?
CLSD stock is listed on the Nasdaq exchange.
What is the outstanding short interest for CLEARSIDE BIOMEDICAL INC?
The outstanding short interest for CLEARSIDE BIOMEDICAL INC (CLSD) is 1.85% of its float.
CLSD Technical Analysis
CLSD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CLSD. Both the profitability and financial health of CLSD have multiple concerns.
CLSD Financial Highlights
Over the last trailing twelve months CLSD reported a non-GAAP Earnings per Share(EPS) of -2.75. The EPS decreased by -472.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -180.75% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CLSD Forecast & Estimates
13 analysts have analysed CLSD and the average price target is 64.26 USD. This implies a price increase of 2362.07% is expected in the next year compared to the current price of 2.61.
For the next year, analysts expect an EPS growth of -631% and a revenue growth 107.81% for CLSD